GURUFOCUS.COM » STOCK LIST » USA » NYSE » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Cash-to-Debt
Switch to:

Myovant Sciences Cash-to-Debt

: 0.97 (As of Jun. 2022)
View and export this data going back to 2016. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Myovant Sciences's cash to debt ratio for the quarter that ended in Jun. 2022 was 0.97.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Myovant Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Myovant Sciences's Cash-to-Debt or its related term are showing as below:

MYOV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.42   Med: 1.85   Max: No Debt
Current: 0.97

During the past 7 years, Myovant Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.42. And the median was 1.85.

MYOV's Cash-to-Debt is ranked worse than
84.85% of 1558 companies
in the Biotechnology industry
Industry Median: 11.43 vs MYOV: 0.97

Myovant Sciences Cash-to-Debt Historical Data

The historical data trend for Myovant Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Cash-to-Debt
Premium Member Only Premium Member Only 2.49 1.57 0.63 1.85 1.18

Myovant Sciences Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.67 1.43 1.18 0.97

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Cash-to-Debt falls into.



Myovant Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Myovant Sciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2022 is calculated as:

Myovant Sciences's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Myovant Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Valente Nancy director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Mehra Uneek officer: Principal Financial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Merendino Lauren officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Marek David C director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Lo Andrew 10 percent owner C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142
Viking Global Equities Master Ltd. 10 percent owner 55 RAILROAD AVENUE GREENWICH CT 06830
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094

Myovant Sciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)